Validation and comparison of quality‐of‐life measures for topical 5‐fluorouracil treatment: results from a randomized controlled trial

Summary Background Topical 5‐fluorouracil (5‐FU) is commonly used for high‐risk patients with keratinocyte carcinoma (KC). Skindex and Skin Cancer Index (SCI) are validated instruments to measure quality of life (QoL) of patients with KC and those who have had surgical treatment of KCs. Aim To valid...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical and experimental dermatology Vol. 42; no. 5; pp. 488 - 495
Main Authors:	Pomerantz, H., Chren, M.‐M., Lew, R., Weinstock, M. A., Hogan, D, Eilers, D., Swetter, S., Chen, S. C., Jacob, S., Warshaw, E. M., Stricklin, G., Dellavalle, R. P., Konnikov, N., Werth, V., Sidhu‐Malik, N., Keri, J., Swan, J. W., Nord, K., Pollack, B., Kempiak, S., High, W., Fett, N., Hall, R.l P., Alonso‐Llamazares, J.r, Rodriguez, G.
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 01-07-2017
Subjects:	5-Fluorouracil Administration, Cutaneous Analysis of Variance Cream Female Fluorouracil - therapeutic use Humans Male Quality of Life Risk groups Skin cancer Skin Neoplasms - prevention & control Surveys and Questionnaires Toxicity Veterans
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Background Topical 5‐fluorouracil (5‐FU) is commonly used for high‐risk patients with keratinocyte carcinoma (KC). Skindex and Skin Cancer Index (SCI) are validated instruments to measure quality of life (QoL) of patients with KC and those who have had surgical treatment of KCs. Aim To validate Skindex and SCI for topical 5‐fluorouracil (5‐FU) application and to compare the two QoL instruments. Methods We randomized 932 veterans at high risk for developing a KC to either topical 5‐FU or vehicle control cream applied to the face and ears for up to 1 month. We collected their Skindex‐29 and SCI scores at baseline and follow‐up visits. Results Compared with controls, 5‐FU reduced QoL, measured by the Skindex symptom, Skindex function and SCI social subscales (P < 0.001, P < 0.01, P = 0.02, respectively). At 1 month, significant changes in QoL in the 5‐FU group were observed in the Skindex symptom (10.1, 95% CI 0.36–12.6), Skindex function (6.0, 95% CI 4.0–8.0) and SCI social (−3.5, 95% CI −6.2 to −0.8) subscales, while the other subscales of Skindex and SCI did not show significant changes. All three Skindex subscales at 1 month correlated with patient‐reported symptom score and photograph‐based toxicity score, whereas social subscale was the only one of the SCI subscales that correlated with patient‐reported symptom and photograph‐based toxicity scores. Conclusions Our study validated Skindex symptom, Skindex function and SCI social subscales for QoL measurement during treatment with topical 5‐FU. The study could not provide evidence for construct validity of the other subscales. Skindex was more responsive than SCI in the context of 5‐FU treatment.
ISSN:	0307-6938 1365-2230
DOI:	10.1111/ced.13089